Sex differences between Veterans participating in interdisciplinary chronic pain rehabilitation

Jennifer L. Murphy, PhD;¹²* Kristin M. Phillips, PhD;¹ Samantha Rafie, PhD¹
¹James A. Haley Veterans’ Hospital, Tampa, FL; ²University of South Florida, Tampa, FL

Abstract—The improved management of pain among the growing number of female Veterans receiving care through the Veterans Health Administration has been established as a priority, but studies suggest that females may respond differently to pain treatment. This study explored differences between female and male Veterans engaged in a Chronic Pain Rehabilitation Program and determined how female and male Veterans change following participation. Veterans (N = 324) in a 3 wk inpatient program completed self-report measures at admission, discharge, and 3 mo follow-up. Participants were 21% female (n = 67) and 79% male (n = 257). Compared with males, females were younger and less likely to be white or married/partnered. Females reported shorter pain duration and were more likely to have primary head or limb pain. At admission, fewer females were prescribed opioids than males and at lower doses. After opioid cessation in the program, however, there were no significant differences in use between the sexes at follow-up. Improvements in a range of domains were sustained at follow-up for both sexes, but females did not maintain gains in pain intensity or sleep while males reported more pain-related fear at discharge and follow-up. This study adds to the literature on sex-specific variations in chronic pain and implications for treatment.

Key words: chronic pain, females, gender, interdisciplinary treatment, multidisciplinary treatment, noncancer pain, opioids, pain rehabilitation, sex differences, treatment outcomes, Veterans, women.

INTRODUCTION

Chronic pain is prevalent among Veterans, and its treatment is a top priority for the Department of Veterans Affairs (VA) [1]. Female Veterans, whose use of VA healthcare has almost doubled in the last decade, are the fastest growing subset of the Veteran population [2]. It is projected that women will comprise 10 percent of the population treated in the VA by 2018 and over 14 percent by 2033 [3]. Female Veterans are younger on average than men, with 42 percent between the ages of 18 and 44, while only 13 percent of males are under 45 [2]. Among Operation Iraqi Freedom (OIF), Operation Enduring Freedom (OEF), and Operation New Dawn (OND) Veterans, 51 percent of women are younger than 44 yr old [4]. In addition, female Veterans are more heterogeneous racially and ethnically, with 39 percent endorsing a minority background versus 23 percent of males [2].

Abbreviations: ANOVA = analysis of variance; CBT = cognitive behavioral therapy; CNP = chronic noncancer pain; CPRP = Chronic Pain Rehabilitation Program; CPS = chronic pain syndrome; CT = catastrophizing subscale; IMMPACT = Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; MED = morphine equivalent dose; NRS = numeric rating scale; OEF = Operation Enduring Freedom; OIF = Operation Iraqi Freedom; OND = Operation New Dawn; POQ-VA = Pain Outcomes Questionnaire-VA; SIS = Symptom Implausibility Scale; SPQ = Sleep Problems Questionnaire; VA = Department of Veterans Affairs.

*Address all correspondence to Jennifer L. Murphy, PhD; James A. Haley Veterans’ Hospital, Pain Clinic G-38, 13000 Bruce B. Downs Blvd, Tampa, FL 33612; 813-972-2000, ext 5239; fax: 813-631-6760.
Email: Jennifer.Murphy2@va.gov
http://dx.doi.org/10.1682/JRRD.2014.10.0250
Data indicate that 57 percent of OIF/OEF/OND females have enrolled in and are using VA services [4]. Women most likely to enroll in VA care have greater psychosocial stressors such as low income, poor health status, and lack of social support [5].

Among the general population, chronic pain is more common in women than men [6]. Studies of experimental pain suggest that women exhibit heightened pain sensitivity [7], experience more intense and frequent pain [8], and report a broader range of pain locations [9]. There is less known about sex differences among the Veteran population specifically. In a large-scale study of OIF/OEF Veterans, the probability of having persistent pain did not differ between sexes, but women were more likely to experience moderate to severe pain [10]. Another study revealed that at years 1 through 7 postdeployment, women were more likely than men to have back, joint, and musculoskeletal pain, and the odds of having these conditions increased for women compared with men each year following deployment [11]. The most prevalent medical condition reflected in VA records for both sexes was musculoskeletal conditions at 55.9 percent for females and 48.5 percent for males [2].

The investigation of sex differences in nonpharmacological pain treatments is lacking and the data available are inconsistent. Jensen et al. found that women, but not men, undergoing cognitive behavioral therapy (CBT) with or without physical therapy exhibited improved health-related quality of life [12]. A study by Hansen et al. investigating various forms of back exercises found that men received greater benefit from conventional physiotherapy than women [13]. Krogstad et al. found that women had significantly more pain reduction than men 2 yr following conservative multimodal care for orofacial pain [14].

While the effectiveness of interdisciplinary pain rehabilitation is well established in the literature [15–17], there is a dearth of data comparing men and women in these settings. In a study of pain tolerance and pain program treatment outcomes between sexes, Edwards et al. found that females demonstrated greater improvement in pain-related disability while males showed more reduction in pain [18]. In addition, females with higher pain tolerances versus those with lower pain tolerances had greater improvements in pain, reduced pain-related interference with functioning, and more activity increases, while pain tolerance was not associated with positive treatment outcomes among males. A study of patients with fibromyalgia following an intensive, outpatient, interdisciplinary pain program showed a better outcome on some scales of the 36-Item Short Form Health Survey for males compared with females in a study by Hooten et al. [19]. Most similar to the current study, Keogh et al. compared 98 patients with complex pain syndromes who participated in a 3 to 4 wk group-based interdisciplinary pain management program at discharge and 3 mo follow-up [20]. Although both sexes showed similar gains at program completion, males maintained gains after 3 mo and females did not. Pieh et al. did not examine follow-up data but found that in a 5 wk daily outpatient pain program, females improved more than males despite there being no significant differences at program admission, including in areas such as pain duration, pain-related disability, and psychiatric comorbidities [21].

The growing number of female Veterans, many of whom will inevitably experience chronic pain, makes the acquisition of knowledge about their characteristics, conditions, and treatment of paramount importance to more effectively serve this population. While pain is a significant problem for both sexes in the VA, female Veterans may have additional risk factors for the development of chronic pain, such as higher rates of injury during initial training [22] as well as higher rates of depression [23] and military sexual trauma [24]. These factors and others may affect the optimal approach to pain care among females and the development of sex-specific pain programs.

To our knowledge, no previous studies have investigated sex differences in population characteristics or treatment outcomes within an interdisciplinary pain setting in the Veteran population. To address this issue, we compared multidomain treatment outcomes of female and male Veterans with chronic noncancer pain (CNP) who participated in a 3 wk residential interdisciplinary chronic pain treatment program. Participants were assessed at three time points: admission, discharge, and 3 mo follow-up. The first aim was to explore differences in demographic and clinical variables between the sexes. The second aim was to determine whether there were differences between how females and males changed over time in pain outcomes. The findings in the literature in this area are limited and mixed; however, based on the most similar study in a civilian population [20], we hypothesized that both groups would demonstrate improvements from admission to discharge but that males would maintain more gains than females at the 3 mo follow-up.
Methods

Participants and Procedures

The current study is a retrospective data analysis of Veterans with CNP who were admitted to the inpatient Chronic Pain Rehabilitation Program (CPRP) at the James A. Haley Veterans’ Hospital in Tampa, Florida, between August 2006 and April 2011. The CPRP is an intensive 3 wk residential, interdisciplinary chronic pain treatment program with a rehabilitation philosophy that seeks to assist those with CNP by teaching self-management skills that will improve quality of life and overall functioning. Patients who participate in the CPRP often have had little pain relief from various pharmacologic trials, interventional and surgical procedures, physical therapy, or complementary or alternative medicine approaches. They typically meet criteria for chronic pain syndrome (CPS) (International Classification of Diseases-9th Revision-Clinical Modification code 338.4) [25], which is defined as chronic pain with significant psychosocial dysfunction. CPS is characterized by unsuccessful pain relief through conventional medical treatments; functional impairment in most domains of life; and negative emotional factors related to pain such as depression, anxiety, and irritability. The CPRP uses a biopsychosocial approach and targets the physical and emotional effects of pain with a focus on active treatment modalities including graduated physical therapy, aquatic therapy, daily paced walking, relaxation techniques, occupational therapy, recreational therapy, individual psychotherapy, educational groups, and family interventions as appropriate.

In addition, effective medication management is an important program goal and includes cessation of all opioids and centrally acting muscle relaxants. The use of other nonopioid analgesics are reviewed at admission and adjusted throughout treatment. Each participant’s medication records were reviewed for the period in which they participated in the CPRP to confirm opioid use status at admission and to extract a taper dose. For those on opioids at admission, initial daily opioid dosing was calculated from the medication records based on the highest opioid taper dose dispensed in the first 3 d of the program. This dose was converted to a morphine equivalent dose (MED) for comparison purposes using established methods [26].

A cognitive-behavioral, biopsychosocial model serves as the basis of treatment. Treatment in the CPRP provides 6 to 8 h per day of supervised therapeutic programming during 15 consecutive workdays, coupled with an additional 2 to 3 h of daily independent, goal-directed assignments (e.g., walking and exercise program, relaxation techniques). Weekend treatment includes recreational and social activities as well as twice-daily exercise, walking, and relaxation sessions.

Prior to CPRP admission, those interested in participating in the program were evaluated for medical and psychiatric stability. Medical needs that may have precluded patients from full engagement and maximum benefit, thus excluding them from participation, included further evaluation by cardiology, neurosurgery, or pulmonology. Psychological barriers for participation included psychiatric hospitalization or illicit drug use within 90 d prior to screening. Those excluded from admission but interested in participating in the program were provided with treatment recommendations and rescreened at a future date.

Measures

Outcome measures reported in this study were administered at three time points. All participants initially completed measures within the first 2 d of admission to the CPRP. Participants were readministered and completed measures within 2 d of discharge from the program. Finally, they were mailed the questionnaires with return postage at 3 mo postdischarge and returned the packet via standard U.S. Postal Service. Questionnaires measured pain intensity and treatment outcomes across the major pain-related domains of functioning, catastrophizing, and sleep. Data regarding medications were retrospectively extracted from participants’ electronic medical records.

Pain intensity was assessed using an 11-point pain numeric rating scale (NRS) to measure “usual” (average) pain over the last week. NRSs are reliable and valid methods for assessing pain intensity [27]. The NRS was anchored with the phrases “no pain” (0) and “worst pain imaginable” (10). The “usual pain” scale has been found to be one of the best measures of pain intensity when compared with alternatives such as “current pain” or “worst pain” [28].

Pain treatment outcomes were assessed using the Pain Outcomes Questionnaire-VA (POQ-VA) [29], which is a multidomain pain assessment instrument developed and validated specifically for Veterans. The POQ-VA assesses treatment outcomes across the major pain-related domains of functioning identified by the Rehabilitation
Accreditation Commission (2002) as essential for comprehensive outcome measurement [29]. POQ-VA scales include interference with mobility, negative affect, vitality (i.e., strength and endurance), and pain-related fear (i.e., avoidance motivated by fear of pain or reinjury). The POQ-VA scales have been shown to have high internal reliability and good stability [30], strong generalizability, and good discriminant and concurrent validity, and they have demonstrated sensitivity to treatment-related change [31]. The POQ-VA also contains an experimental scale that was developed as a measure of highly improbable pain-related symptoms (the Symptom Implausibility Scale [SIS]). The SIS consists of 10 items describing a range of unusual pain symptoms or complaints.

Pain catastrophizing was assessed using the 6-item catastrophizing subscale (CT) from the revised 26-item Coping Strategies Questionnaire [32]. The CT has adequate internal consistency (0.72) and has been shown to negatively correlate with measures of activity [32]. Catastrophizing also has been positively correlated with depressive symptomatology [33–34], negative affectivity [35], exaggerated emotional response to aversive stimuli [36], and expectation of pain and psychological distress [37].

Sleep was assessed using the Sleep Problems Questionnaire (SPQ) [38]. The SPQ is a 4-item measure of the most typical symptoms of poor sleep in both healthy and distressed populations. Responses are based on the number of days during the week that each sleep symptom occurs, and these 0 to 7 item scores are summed for an overall sleep symptom measure. The scale has good internal consistency and validity [38].

**Data Analysis**

In preliminary analyses, the demographic and clinical characteristics of participants based on sex were compared using t-tests for continuous variables and chi-square tests for categorical variables. When categorical variables included more than two categories and the overall chi-square test was significant, subsequent Bonferroni-corrected group comparisons were conducted for each category. To determine whether demographic and clinical variables for which there were significant differences between groups should be considered as potential control variables, the interaction with each of these variables with sex was evaluated for the pain variables at admission. Those variables that had significant interactions with sex would be retained as control variables.

To examine longitudinal changes in pain outcome variables across the three time points, repeated-measures analyses of variance (ANOVAs) were conducted using SPSS version 19 (IBM Corporation; Armonk, New York). Initial analysis consisted of a 2 (group: females, males) × 3 (time: admission, discharge, follow-up) ANOVA for each outcome variable. The main effects of sex and time and interaction effects for sex × time were evaluated. Quadratic terms were included to determine whether there were nonlinear effects (e.g., plateaus or decrements in pain outcomes following improvement). Differences between males and females at each time point were evaluated using independent samples t-tests and within-group differences from admission to discharge and discharge to follow-up were evaluated using paired-samples t-tests. A p-value of 0.05 (two-tailed) was used for statistical significance. Effect sizes were calculated using Cohen’s d. An effect size of 0.2 to 0.3 is considered small, 0.5 medium, and ≥0.8 large [39]. The study was powered at 0.80 to detect an effect size of \( f = 0.25 \) for the interaction between sex and time, assuming a per group sample size of 80 and alpha = 0.05. The study was also powered at 0.80 to detect an effect size of \( f = 0.14 \) for within-group change across the three measurement points.

**RESULTS**

**Preliminary Analyses**

Veterans (N = 324) completed self-report measures at admission, discharge, and 3 mo follow-up. Participants were 21 percent female (n = 67) and 79 percent male (n = 257). Table 1 presents demographic and clinical characteristics of participants. Regarding demographic factors, there were several significant differences. Females were younger, with an average age of 47.19 yr, while males were 52.77 yr on average (t(320) = 3.81, p < 0.001). The majority of female participants in this study were unmarried and not cohabiting with a partner (67%, n = 45), compared with males who tended to be married or living with a partner (63%, n = 162) (\( \chi^2 (1, N = 324) = 19.21, p < 0.001 \)). Finally, females were less likely to be white (\( \chi^2 (2, N = 324) = 6.86, p = 0.03 \)), at 61 percent (n = 41) versus 76 percent (n = 195) of males. Regarding clinical factors, females had a shorter pain duration (t(320) = 2.53, p = 0.01) of 9.35 yr on average versus males at 12.99 yr on average. They were less likely to have a
primary complaint of back pain (females: 45%, n = 30; males: 58%, n = 149), but more likely to report primary pain location in head (e.g., headache) (females: 12%, n = 8; males: 5%, n = 13) ($\chi^2(4, N = 324) = 11.67, p = 0.02$) or the limb (e.g., leg, arm) (females: 21%, n = 14; males: 10%, n = 26).

Regarding opioid use at admission, 35 percent of all participants were prescribed opioids; however, females were less likely to be prescribed opioids (24%) than males (38%) ($\chi^2(1, N = 324) = 4.73, p = 0.03$). Among participants who were taking opioids, females had lower MEDs at admission compared with males ($t(62) = 3.18, p = 0.002$). Per CPRP standard of care, no participants were taking opioids at discharge. At follow-up, 17 percent of all participants reported opioid use; however, there were no differences in opioid use between females (18%) and males (17%) ($\chi^2(1, N = 312) = 0.05, p = 0.83$).

Given the difference between sexes in the previously mentioned demographic and clinical factors, we evaluated whether any should be included as covariates by evaluating the effect of their interaction with sex on each outcome variable. Despite these differences, there were no significant interactions for sex × age, sex × marital status, sex × race, sex × pain duration, sex × primary pain location, or sex × opioid use for any outcome ($p > 0.05$); therefore, these variables were not included as covariates.

To evaluate differences between groups on pain outcomes at admission, we used $t$-tests. There were significant differences between females (18%) and males (17%) ($\chi^2(1, N = 312) = 0.05, p = 0.83$).

### Change Over Time in Pain Outcomes by Sex

For pain intensity, there was a significant linear effect of time ($F(1,321) = 16.70, p < 0.001$). However, there was no group × time interaction ($F(1,321) = 0.12, p = 0.73$), quadratic group × time interaction ($F(1,321) = 1.39, p = 0.24$), or main effect for group ($F(1,321) = 0.02, p = 0.88$). There were no significant differences between sexes at any time point. Comparing time effects for each group separately indicated that both females and males

### Table 1.

Differences between sexes on demographic and clinical factors. Data presented as mean ± standard deviation or percentage.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Female ($n = 67$)</th>
<th>Male ($n = 257$)</th>
<th>$p$-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>47.19 ± 9.33</td>
<td>52.77 ± 11.01</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Education (yr)</td>
<td>14.25 ± 1.89</td>
<td>13.75 ± 2.60</td>
<td>0.14</td>
</tr>
<tr>
<td>Pain Duration (yr)</td>
<td>9.35 ± 7.95</td>
<td>12.99 ± 11.07</td>
<td>0.01</td>
</tr>
<tr>
<td>Taking Opioids at Admission</td>
<td>24</td>
<td>38</td>
<td>0.03</td>
</tr>
<tr>
<td>MED at Admission*</td>
<td>39.63 ± 24.68</td>
<td>69.31 ± 69.18</td>
<td>0.002</td>
</tr>
<tr>
<td>Taking Opioids at Discharge</td>
<td>18</td>
<td>17</td>
<td>0.83</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Black</td>
<td>28</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>61$^a$</td>
<td>76$^b$</td>
<td></td>
</tr>
<tr>
<td>Asian, American Indian, or Other</td>
<td>11</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Employment at Admission</td>
<td></td>
<td></td>
<td>0.23</td>
</tr>
<tr>
<td>Employed</td>
<td>10</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Unemployed</td>
<td>90</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>Relationship Status</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Married or Living with Partner</td>
<td>33</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Not Married or Not Living with Partner</td>
<td>67</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Primary Pain Site</td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>Back</td>
<td>45$^a$</td>
<td>58$^b$</td>
<td></td>
</tr>
<tr>
<td>Limb</td>
<td>21$^a$</td>
<td>10$^b$</td>
<td></td>
</tr>
<tr>
<td>Neck</td>
<td>9</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Head</td>
<td>12$^a$</td>
<td>5$^b$</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>13</td>
<td>15</td>
<td></td>
</tr>
</tbody>
</table>

Note: Superscript letters refer to Bonferroni-corrected group comparisons that revealed significant differences between groups in this category at $p < 0.05$.

*Among those taking opioids.

MED = morphine equivalent dose.
reported improved pain from admission to discharge \((p < 0.05)\). However, this reduction was only maintained at follow-up for males. That is, males reported improved pain from admission to follow-up \((t(255) = 5.19, p < 0.001)\), whereas there was only a trend toward improvement in pain intensity for females from admission to follow-up \((t(66) = 1.74, p = 0.09)\). Effect sizes calculated from admission to discharge indicate small effects for males \((d = 0.4)\) and medium effects for females \((d = 0.5)\), and small effects for both at follow-up \((d = 0.3)\).

For pain-related fear, a significant linear effect of time was found \((F(1,318) = 26.17, p < 0.001)\). There was also a significant main effect for group \((F(1,318) = 8.25, p = 0.004)\) (Figure). Planned comparisons indicated that both groups demonstrated improvements from admission to discharge and from admission to follow-up \((p < 0.05)\). However, comparing the sexes at each time point indicates that females and males reported equivalent levels of pain-related fear at admission \((t(322) = 1.37, p = 0.17)\), but males reported higher levels of pain-related fear than females at discharge \((t(322) = 2.55, p = 0.01)\) and follow-up \((t(318) = 3.03, p = 0.003)\). Effect sizes calculated from admission to discharge indicated medium effects for

Table 2.
Mean ± standard deviation of outcome variables by group.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Admission</th>
<th>Discharge</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>6.94 ± 1.57</td>
<td>6.07 ± 1.93</td>
<td>6.42 ± 2.48</td>
</tr>
<tr>
<td>Male</td>
<td>6.88 ± 1.73</td>
<td>6.19 ± 1.80</td>
<td>6.26 ± 2.06</td>
</tr>
<tr>
<td>Highest Pain Level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8.46 ± 1.43</td>
<td>7.97 ± 1.80</td>
<td>7.66 ± 2.28</td>
</tr>
<tr>
<td>Male</td>
<td>8.50 ± 1.29</td>
<td>7.95 ± 1.64</td>
<td>7.89 ± 1.85</td>
</tr>
<tr>
<td>Pain Interference in Mobility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>25.00 ± 9.96</td>
<td>20.55 ± 10.70</td>
<td>21.34 ± 12.41</td>
</tr>
<tr>
<td>Male</td>
<td>25.06 ± 10.15</td>
<td>21.72 ± 10.55</td>
<td>22.97 ± 10.99</td>
</tr>
<tr>
<td>Pain-Related Negative Effect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>27.88 ± 11.33</td>
<td>21.84 ± 11.98</td>
<td>25.70 ± 11.55</td>
</tr>
<tr>
<td>Male</td>
<td>28.05 ± 11.34</td>
<td>23.70 ± 11.95</td>
<td>27.55 ± 12.56</td>
</tr>
<tr>
<td>Pain Interference in Vitality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>21.42 ± 4.43</td>
<td>16.39 ± 5.15</td>
<td>18.89 ± 5.27</td>
</tr>
<tr>
<td>Male</td>
<td>19.95 ± 5.27</td>
<td>15.92 ± 5.38</td>
<td>18.59 ± 5.24</td>
</tr>
<tr>
<td>Pain-Related Fear</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10.88 ± 5.26</td>
<td>7.25 ± 4.27</td>
<td>8.64 ± 4.44</td>
</tr>
<tr>
<td>Male</td>
<td>11.77 ± 4.55</td>
<td>8.88 ± 4.75</td>
<td>10.60 ± 4.78</td>
</tr>
<tr>
<td>Implausible Symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>48.36 ± 18.46</td>
<td>32.04 ± 20.02</td>
<td>39.09 ± 24.39</td>
</tr>
<tr>
<td>Male</td>
<td>47.19 ± 20.75</td>
<td>35.96 ± 21.07</td>
<td>42.24 ± 24.11</td>
</tr>
<tr>
<td>Sleep</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>21.48 ± 5.76</td>
<td>15.73 ± 7.84</td>
<td>20.05 ± 8.65</td>
</tr>
<tr>
<td>Male</td>
<td>21.18 ± 6.86</td>
<td>17.80 ± 7.99</td>
<td>20.10 ± 7.79</td>
</tr>
<tr>
<td>Pain Catastrophizing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>19.93 ± 8.89</td>
<td>12.33 ± 8.37</td>
<td>13.91 ± 9.24</td>
</tr>
<tr>
<td>Male</td>
<td>19.03 ± 9.56</td>
<td>13.00 ± 9.36</td>
<td>16.22 ± 10.31</td>
</tr>
</tbody>
</table>

![Figure](image.png)

**Figure.** Effect of sex on pain-related fear.
males ($d = 0.6$) and large effects for females ($d = 0.8$), which decreased at follow-up to small effects for males ($d = 0.3$) and medium effects for females ($d = 0.5$).

For mobility, a significant linear effect of time was found ($F(1,296) = 17.08, p < 0.001$). However, there was no group × time interaction ($F(1,296) = 0.87, p = 0.35$), quadratic group × time interaction ($F(1,296) = 0.01, p = 0.94$), or main effect for group ($F(1,296) = 0.47, p = 0.49$). There were no significant differences between sexes at any time point. Both females and males reported less pain-related interference with mobility from admission to discharge ($p < 0.05$), and both groups maintained this improvement at follow-up ($p < 0.05$), suggesting sex did not play a significant role in improvements in pain-related interference in mobility.

For pain-related negative affect, a significant quadratic effect of time was found ($F(1,317) = 64.46, p < 0.001$); however, the linear time effect was not significant ($p = 0.08$). There was no group × time interaction ($F(1,317) = 1.14, p = 0.29$), quadratic group × time interaction ($F(1,317) = 0.73, p = 0.40$), or main effect for group ($F(1,317) = 0.86, p = 0.36$). There were no significant differences between sexes at any time point. Both females and males reported improved pain-related negative affect from admission to discharge ($p < 0.05$), but these effects were not maintained at follow-up. That is, males returned to their pretreatment levels of pain-related negative affect by follow-up ($t(252) = 0.74, p = 0.46$) and females had only a trend toward improved affect from admission to follow-up ($t(66) = 1.71, p = 0.09$).

For vitality, a significant linear effect of time was found ($F(1,313) = 21.72, p < 0.001$). There was no group × time interaction ($F(1,313) = 1.18, p = 0.28$), quadratic group × time interaction ($F(1,313) = 0.03, p = 0.87$), or main effect for group ($F(1,313) = 1.50, p = 0.22$). At admission, females reported higher levels of pain-related interference in vitality; however, there were no significant differences between the sexes at discharge or follow-up. Both groups demonstrated improvements from admission to discharge and from admission to follow-up ($p < 0.05$), suggesting sex did not play a significant role in improvements in pain-related interference in vitality.

For implausible symptoms, a significant linear effect of time was found ($F(1,280) = 19.22, p < 0.001$). There was no group × time interaction ($F(1,280) = 1.60, p = 0.21$), quadratic group × time interaction ($F(1,280) = 0.00, p = 0.97$), or main effect for group ($F(1,280) = 0.22, p = 0.64$). There were no significant differences between sexes at any time point. Both groups demonstrated improvements from admission to discharge and from admission to follow-up ($p < 0.05$), suggesting sex did not play a significant role in improved reports of implausible symptoms.

For sleep, a significant linear effect of time was found ($F(1,303) = 5.13, p = 0.02$). There was no group × time interaction ($F(1,303) = 0.12, p = 0.73$), quadratic group × time interaction ($F(1,303) = 1.72, p = 0.19$), or main effect for group ($F(1,303) = 0.33, p = 0.57$). There were no significant differences between sexes at any time point. Comparing time effects for each group separately indicated that both groups demonstrated improvements from admission to discharge ($p < 0.05$). However, at follow-up this reduction was only maintained for males. That is, males reported improved overall sleep from admission to follow-up ($t(244) = 2.21, p = 0.03$), whereas the change for females from admission to follow-up was not significant ($t(60) = 1.38, p = 0.17$). Effect sizes calculated from admission to discharge indicated medium effects for males ($d = 0.5$) and large effects for females ($d = 0.8$), which decreased for both groups at follow-up to small effects ($d = 0.1$ and $0.2$, respectively).

For catastrophizing, a significant linear effect of time was found ($F(1,304) = 23.41, p < 0.001$). There was no group × time interaction ($F(1,304) = 2.45, p = 0.12$), quadratic group × time interaction ($F(1,304) = 0.00, p = 0.99$), or main effect for group ($F(1,304) = 0.75, p = 0.39$). There were no significant differences between the sexes at any time point. Both groups demonstrated improvements from admission to discharge and from admission to follow-up ($p < 0.05$), suggesting sex did not play a significant role in improvements in pain catastrophizing.

**DISCUSSION**

Consistent with previous findings, this study provides additional support regarding the benefits of interdisciplinary pain rehabilitation across a range of domains for both males and females. The results of this retrospective examination supported our hypothesis that while both males and females demonstrated significant improvements from admission to discharge, males maintained more gains than females at follow-up. The differential effects between sexes suggest potential considerations for future clinical care and investigation to maximize the benefits of interdisciplinary chronic pain treatment.
Distinctions were found among sexes in several areas. Demographically, females were younger, less likely to be white, and less likely to be married or partnered. They had shorter pain durations, were less likely to have back pain, more likely to have head or limb pain, and less likely to be prescribed opioids. If taking opioids, they were on a lower daily MED. At admission, females reported more pain-related interference in vitality (i.e., strength and endurance), but there were no differences at discharge or follow-up. At discharge, both males and females reported significant improvements on all outcome variables; however, there were differences between males and females at the 3 mo follow-up.

While both sexes reported improved pain intensity from admission to discharge, females did not maintain pain reduction gains at 3 mo follow-up. This is similar to Keogh et al.’s finding, where females returned to baseline levels of pain intensity versus males [20]. While both sexes had statistically significant decreases in pain intensity at discharge, the effect sizes for females were medium, indicating a clinically significant change [29], whereas the effect size for males was small, meaning females actually made greater gains while in the program but were unable to maintain them. At 3 mo, effect sizes were small across sexes; however, it is important to note that the treatment modality is a tertiary-level inpatient pain rehabilitation program in which the population served represents those individuals who have the most chronic and treatment-refractory conditions. Because of this, the focus is on improving quality of life and function across domains despite the chronicity of the pain condition and any decrease in pain intensity is noteworthy.

In addition, while overall sleep improved during the course of program participation for both sexes, only males maintained gains in overall sleep at follow-up. The gains for both at discharge were statistically significant and the effect size for females was large, indicating a clinically significant change [29], whereas the effect size for males was medium. As with pain, females made greater gains while in the program but were unable to maintain them, and effects across sexes were small at 3 mo. While greater clinical significance at follow-up would have been preferred, the prevalence of sleep issues in the treated population, including sleep-disordered breathing conditions and medical comorbidities, make even small changes meaningful.

On the variable related to avoidance of activity due to fear of increased pain and/or reinjury, females and males were equivalent at admission and both sexes demonstrated significant improvement over time; however, males reported higher levels of pain-related fear than females at both discharge and follow-up. Interestingly, in a study of sex and gender in the experience of pain, Ramirez-Maestre and Esteve found that fear-avoidance was associated with pain intensity in males but not females [40]. Both groups maintained improvements in mobility, vitality, endorsement of implausible symptoms, and catastrophizing. While some previous studies have found that females reported higher levels of catastrophizing, the results of the present study are consistent with Ramirez-Maestre and Esteve [40] and Unruh et al. [41] who did not find sex differences in this variable. Both females and males reported improved negative affect at program discharge, but the effects were not maintained for either group at follow-up.

This study highlights several areas for future research and clinical consideration. While the efficacy of interdisciplinary pain care has been well established in the literature, there is limited research examining sex differences in this treatment modality and available studies reflect inconsistent outcomes. Increased attention is warranted, and focusing on why and how specific aspects of treatment may affect the sexes differently would be particularly beneficial to enhance understanding. This would help to shed light on treatment decisions and inform whether programs should be altered based on the specific needs of females. Furthermore, future research should evaluate whether an intervention targeted to females can produce stronger effects and what aftercare treatment is most effective at maintaining those effects.

Across the literature regarding female Veterans with pain, the population is younger, and less likely to be white or married than their male peers. These consistent demographic findings have several potential implications. Females in the VA are more likely to be transitioning from the military and concomitantly contemplating choices about pursuing employment or additional education. Since they are more ethnically and racially diverse, it is essential to be aware of how their preferences and needs may differ. The fact that they are less likely to be married highlights the importance for independence both financially and in the home, as well as the potential implications of single parenting. When considering the treatment of females with pain or developing sex-specific programs, focusing on areas such as adjustment and transitional issues,
vocational options, culturally sensitive diversity topics, gender roles (including parenting), and independent functioning should be emphasized. As is true of females in the general population, headaches were more common among females in this study. Because of this, it is also important to consider an enhanced role for the evaluation and treatment of headaches within pain rehabilitation programs.

Examining differences in VA and Department of Defense prescribing practices for females versus males also warrants further investigation. While lower dosing is likely, at least in part because of average weight differences between the sexes, in this study, females were also less likely to be prescribed opioids at all. This finding conflicts with evidence from the public sector that females are actually more likely to be prescribed opioids. The reasons for the opioid use patterns in this sample are unclear, although there are several possibilities. Since chronic opioid therapy is typically not indicated for headache pain, which was more prevalent among females, that may account for some of the difference. Females may have received higher dosages of other analgesics such as muscle relaxants, though we do not know because medications other than opioids were not assessed at admission. It is also possible that females were undertreated or undermedicated compared with males [42]. Additionally, the literature indicates that females are more likely to be referred to mental health specialists when presenting for pain complaints [41].

Perhaps the most important issue that this study raises is determining the optimal follow-up needs for females as well as males following intensive rehabilitation. Effect sizes ranged from small to large at discharge and tended to decrease at follow-up. This trend indicates that all patients would likely benefit from additional maintenance treatment following program discharge to sustain effects. Programmatically, clinical responses in the CPRP have been to schedule an earlier postdischarge visit or contact (i.e., at 1 mo vs 3 mo) to evaluate implementation and make any needed interventions as soon as possible. Aftercare options have also been expanded to include several stepped groups to expand duration. However, although effect sizes were generally small at follow-up, suggesting limited clinical significance, the modest improvements should be balanced against the fact that those in the program had longstanding CPS and the vast majority of Veterans who tapered off of opioid analgesics during treatment did not return to use.

While females did as well as or better than males during treatment, their self-reported pain intensity did not remain significantly improved 3 mo after discharge, which was consistent with previous findings [20]. They also did not retain sleep gains, and neither group maintained improvements in negative affect at follow-up. For females, since they made greater gains in several areas during treatment but did not maintain them, enhanced aftercare should be considered strongly in any sex-specific pain programs. Identifying specific information about why regression for both sexes may have occurred is important in understanding how to prevent the return to baseline functioning in these areas in the future. Clarification regarding the obstacles that may have prevented the implementation of acquired self-management strategies would be useful in the development of an enhanced plan of care prior to discharge and may improve long-term outcomes. Furthermore, since the cohort that receives comprehensive tertiary-level care is likely to have greater psychiatric needs than the general chronic pain population regardless of sex, more intensive mental health support following treatment may be indicated, as the lack of maintenance regarding affective gains suggests.

Finally, the consideration of issues more prevalent among female Veterans should be examined in future research and treatment approaches. For example, since military sexual trauma is reported at screening among one in four female Veterans [43], consideration of options that address both physical pain and trauma are indicated to optimize the efficiency and effectiveness of treatment. Likewise, tailoring treatment to accommodate conditions seen most commonly in females such as headaches, fibromyalgia, and pelvic pain may better serve the needs of this special population. Furthermore, some evidence suggests that using a different therapeutic approach with females such as Acceptance and Commitment Therapy may be more beneficial than a CBT-guided curriculum focused on controlling or changing unwanted thoughts and feelings.

The current study has several limitations that should be acknowledged. First, this was a retrospective design that did not include a control group; thus, no definitive conclusions can be made regarding the intervention. Second, only pain location and negative affect, as reflected on the POQ-VA, were known for program participants. Specific medical and psychiatric diagnostic information was not available and likely would have been helpful in gaining a fuller understanding of the role of comorbidities.
Third, the generalizability of this sample to the general population may be restricted because it was only 21 percent female and all participants had a military history. However, given that females constitute slightly less than 10 percent of the cohort registered for VA care, the higher number of females in this sample likely accurately reflects the prevalence of chronic pain among female Veterans. In addition, having only one point of follow-up at 3 mo was a limitation because we were unable to examine sustained differences over a longer period such as 6 or 12 mo. Finally, while this was not a clinical trial, the use of Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)-recommended measures might have helped in making conclusions more standardized and generalizable. The selected measures were chosen for use in a clinical program due to their applicability to the population; specifically, the POQ-VA is the only pain outcomes measure that was developed and validated for Veterans. Furthermore, IMMPACT core domains such as pain intensity and various key functional areas such as negative affect and mobility are reflected in the POQ-VA.

CONCLUSIONS

The current findings add to a growing body of research suggesting that sex differences may exist in the determinants of pain treatment outcomes. Given the increase in the number of female Veterans entering the VA system, these data are likely to address gaps in our current knowledge of female Veterans’ experiences and needs in pain management and have clinically relevant implications for better serving female Veterans with chronic pain. Additional examination of the differences that may exist between sexes and their implications for effective pain management should continue to be explored.

ACKNOWLEDGMENTS

Author Contributions:
Study concept and design: J. L. Murphy, K. M. Phillips.
Acquisition of data: J. L. Murphy, K. M. Phillips.
Statistical analysis and interpretation of data: K. M. Phillips, S. Rafie.
Drafting of manuscript: J. L. Murphy, K. M. Phillips, S. Rafie.
Critical revision of manuscript for important intellectual content: J. L. Murphy, K. M. Phillips, S. Rafie.
Final approval of manuscript: J. L. Murphy, K. M. Phillips, S. Rafie.

Financial Disclosures: The authors have declared that no competing interests exist.
Funding/Support: This material was unfunded at the time of manuscript preparation.
Additional Contributions: Dr. Rafie is now with the Bay Area Pain and Wellness Center, Los Gatos, California.
Institutional Review: Approval for the data used in this study was obtained from the James A. Haley Veterans’ Hospital Research and Development Review Committee and the University of South Florida Institutional Review Board. Informed consent was not obtained because this is a retrospective study.
Participant Follow-Up: The authors do not plan to inform participants of the publication of this study.
Disclaimer: All opinions expressed herein are those of the authors and do not in any way represent those of the VA, Department of Defense, U.S. Government, or any of its agencies.

REFERENCES


http://dx.doi.org/10.1097/00002508-200309000-00002


http://dx.doi.org/10.1682/JRRD.2003.09.0381


http://dx.doi.org/10.1097/00002508-199706000-00010

http://dx.doi.org/10.1016/0304-3959(94)90050-7

http://dx.doi.org/10.1037/0021-843X.99.3.260

http://www.imdb.com/title/tt7394314/


http://dx.doi.org/10.1016/S0304-3959(00)00430-9

http://dx.doi.org/10.1016/0895-4356(88)90138-2


http://dx.doi.org/10.1016/j.jpain.2014.02.006

http://dx.doi.org/10.1097/00002508-199901000-00006


Submitted for publication October 22, 2014. Accepted in revised form March 9, 2015.

This article and any supplementary material should be cited as follows: